Eli Lilly’s Revenue Mix: Endocrinology Dominates
Eli Lilly and Company, one of the world’s largest pharmaceutical groups, draws nearly three-quarters of its revenue from a single therapeutic area. According to the company’s latest revenue breakdown, endocrinology accounted for 74% of total sales. This category encompasses treatments for diabetes, obesity and growth disorders, with blockbuster GLP-1 and GIP/GLP-1 drugs serving as the main growth engine.
Oncology contributed 14.4% of revenue, followed by immunology at 8.1% and neurology at just 2.1%. The remaining 1.4% was spread across other, smaller areas. Geographically, the United States remains the dominant market with 66.7% of sales, while Europe contributes 17.7%, Japan 3.2%, China 3% and the rest of the world 9.4%.
At the market close on August 7, 2026, Eli Lilly shares traded at $1,185.71, giving the company a market capitalisation of roughly $1,057 billion. The stock has been a standout performer, reflecting investor enthusiasm for its metabolic disease pipeline, though the heavy concentration in one therapeutic field is a feature that cuts both ways.
Why Endocrinology Carries Both Strength and Concentration Risk
The endocrinology franchise is both the star and the structural risk in Lilly’s portfolio. Products such as tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) have propelled the company to record valuations. The 74% revenue share underscores how deeply Lilly’s near-term fortunes are tied to the continued uptake and pricing of incretin-based therapies.
Such concentration leaves the company exposed to any disruption in that niche — whether from competitor innovation, patent expirations, changes in US drug pricing policy or shifts in insurance coverage. With oncology and immunology still relatively modest contributors, a setback in endocrinology would be felt across the entire business. For now, however, the demand trajectory for diabetes and obesity treatments continues to reward that focus.
Comments 0